Research programme: dopamine transporter targeted imaging agents - Alseres
Alternative Names: O 1505; O 1505TLatest Information Update: 12 May 2011
At a glance
- Originator Harvard University
- Developer Alseres Pharmaceuticals
- Class Imaging agents
- Mechanism of Action Dopamine plasma membrane transport protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Parkinson's disease
Most Recent Events
- 14 Sep 2007 Preclinical development is ongoing
- 08 Jun 2007 Boston Life Sciences is now called Alseres Pharmaceuticals
- 17 Aug 2005 Preclinical trials in Parkinson's disease and Atttention-deficit hyperactivity disorder diagnosis in USA (unspecified route)